// App-Quantinova.ai

2840 : CDK4/6 inhibitor PD-0332991 (palbociclib) promotes cell death and synergizes with CPT-11 in colorectal cancer under hypoxia in vitro

Researchers

Presenter

  • Jun Zhang

Principal Investigators

  • Lanlan Zhou

  • Shuai Zhao

  • David Dicker

  • Wafik S. El-Deiry

Medical Centers

  • Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Solid malignancies

  • Colorectal Cancer

  • Breast cancer

  • Lymphomas

  • Non Small Cell Lung cancer

Biomarkers

  • Mitogen-activated protein kinase

  • p53

  • Cyclin dependent kinase 1

  • Cyclin-dependent kinase 4

  • Retinoblastoma protein

  • Extracellular signal-regulated kinase

  • Human epidermal growth factor receptor 2

  • TNF superfamily member 10

Drug/Treatment

  • sangivamycin

  • Palbociclib

  • Oxaliplatin

  • Erbitux

  • Letrozole

  • Irinotecan

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved